- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 (blinded), Placebo, LOU064 (open label)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 644
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diet Habit, Cognitive Function
- Interventions
- No Intervention/Observational Study
- Other
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 104 participants
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Preterm Infants
- Interventions
- 3-hour bundled care, 6-hour bundled care
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 32 Weeks
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Parkinson&Amp;Amp;#39;s Disease (PD)
- Interventions
- Deep-brain Stimulation, Transcranial Magnetic Stimulation, Transcranial Alternating Current Stimulation
- Device
- Lead sponsor
- Nandakumar Narayanan
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 635 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2029
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Acute Myeloid Leukemia
- Interventions
- none (observational study)
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- COPD, Respiratory Tract Disease, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, Lung Diseases
- Interventions
- Wellinks
- Other
- Lead sponsor
- Convexity Scientific Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Contraception, Chronic Disease
- Interventions
- Interview, Observation
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Brain Neoplasm, Low Grade Glioma, Seizure Disorder
- Interventions
- Survey Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Friedreich Ataxia, Rare Diseases
- Interventions
- Geneticlly confirmed disease causing FXN mutatuion, Healthy Control
- Other
- Lead sponsor
- Friedreich's Ataxia Research Alliance
- Other
- Eligibility
- 4 Years to 21 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Philadelphia, Pennsylvania • Memphis, Tennessee
- Conditions
- Dementia, Alzheimer's Disease and Related Dementias
- Interventions
- HomeCare
- Device
- Lead sponsor
- HiDO Technologies
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Autism Spectrum Disorder (ASD)
- Interventions
- Wellness Enhancing Physical Activity for Young Children (WE PLAY), Non-Physical Activity Online Training
- Behavioral
- Lead sponsor
- Northeastern University
- Other
- Eligibility
- 33 Months to 71 Months
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • University Park, Pennsylvania
- Conditions
- Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Danvers, Massachusetts
- Conditions
- Menorrhagia
- Interventions
- Naproxen, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Seattle, Washington
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Behavioral Dietary Intervention, Compliance Monitoring, Counseling, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 687
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more
- Conditions
- Craniopharyngioma
- Interventions
- Radical Surgery or Limited Surgery, Proton Therapy, ^1^8F-fluorodeoxyglucose, ^1^1C-methionine
- Procedure · Device · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2031
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Memphis, Tennessee
- Conditions
- Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
- Interventions
- Axatilimab
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- Metoprolol, Diltiazem
- Drug
- Lead sponsor
- CAMC Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, West Virginia
- Conditions
- Alcohol Use Disorder, Insomnia
- Interventions
- Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence
- Drug · Behavioral · Device
- Lead sponsor
- Sterling McPherson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Sigmoidoscopy
- Procedure
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Postpartum Preeclampsia
- Interventions
- Tight postpartum blood pressure control
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Livingston, New Jersey • New Brunswick, New Jersey
- Conditions
- Optic Nerve Diseases
- Interventions
- Zyvox - linezolid, Matched control
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 7
- States / cities
- Jonesboro, Arkansas • West Palm Beach, Florida • New Orleans, Louisiana + 4 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Idelalisib, Ofatumumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 24
- States / cities
- Duarte, California • Fresno, California • San Diego, California + 21 more
- Conditions
- ICU Acquired Weakness, Post Intensive Care Unit Syndrome, Muscle Weakness, Critical Illness
- Interventions
- Not listed
- Lead sponsor
- Esther Dupont-Versteegden
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 209 participants
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Lexington, Kentucky • Oklahoma City, Oklahoma
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
- Interventions
- Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies
- Behavioral · Other
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Columbia, Missouri